423 related articles for article (PubMed ID: 19110745)
21. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
22. Infliximab treatment in psoriatic arthritis: our experience.
Rioda WT; Adorni G
Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
[TBL] [Abstract][Full Text] [Related]
23. Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial.
Prinz JC; Fitzgerald O; Boggs RI; Foehl J; Robertson D; Pedersen R; Molta CT; Freundlich B
J Eur Acad Dermatol Venereol; 2011 May; 25(5):559-64. PubMed ID: 20840349
[TBL] [Abstract][Full Text] [Related]
24. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents.
Adişen E; Karaca F; Gürer MA
Clin Exp Dermatol; 2008 Mar; 33(2):164-6. PubMed ID: 18257837
[TBL] [Abstract][Full Text] [Related]
25. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
26. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.
Mease PJ; Kivitz AJ; Burch FX; Siegel EL; Cohen SB; Ory P; Salonen D; Rubenstein J; Sharp JT; Tsuji W
Arthritis Rheum; 2004 Jul; 50(7):2264-72. PubMed ID: 15248226
[TBL] [Abstract][Full Text] [Related]
27. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
28. Treatment of psoriasis and psoriatic arthritis.
Papoutsaki M; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
[TBL] [Abstract][Full Text] [Related]
29. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
30. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
31. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors.
Mease PJ
Ann Rheum Dis; 2002 Apr; 61(4):298-304. PubMed ID: 11874829
[TBL] [Abstract][Full Text] [Related]
32. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
[TBL] [Abstract][Full Text] [Related]
33. [A case of granulomatous rosacea coinciding with the use of etanercept: no relapse with infliximab].
Winter UM; Treudler R; Paasch U; Sticherling M; Simon JC
Hautarzt; 2008 Sep; 59(9):724-7. PubMed ID: 18465064
[TBL] [Abstract][Full Text] [Related]
34. Biological agents in the treatment of psoriasis.
Tzu J; Krulig E; Cardenas V; Kerdel FA
G Ital Dermatol Venereol; 2008 Oct; 143(5):315-27. PubMed ID: 18833073
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
36. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Mease PJ; Goffe BS; Metz J; VanderStoep A; Finck B; Burge DJ
Lancet; 2000 Jul; 356(9227):385-90. PubMed ID: 10972371
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
38. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
[TBL] [Abstract][Full Text] [Related]
39. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients.
Zanni M; Missale G; Santilli D; Di Nuzzo S
Eur J Dermatol; 2011; 21(4):564-7. PubMed ID: 21543290
[TBL] [Abstract][Full Text] [Related]
40. Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist.
Wong VK; Lebwohl MG
Expert Opin Biol Ther; 2005 Nov; 5(11):1505-13. PubMed ID: 16255653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]